Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27934356 | 0.84 | HDAC8 (0.44) | ALDH1A1SMN1; SMN2PTGS2 | |
| SCHEMBL22778266 | 0.81 | FFAR1 (0.49) | ALDH1A1PKMMEN1KMT2AMAPT | |
| SCHEMBL15946011 | 0.77 | HTR6 (0.45) | — | |
| SCHEMBL21024666 | 0.77 | KDM4E (0.47) | ALDH1A1ESR1KDM4E | |
| SCHEMBL18896303 | 0.75 | HDAC8 (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2APTGS2 | |
| SCHEMBL21239626 | 0.74 | KEAP1 (0.48) | ALDH1A1SMN1; SMN2PKMMEN1KMT2A | |
| SCHEMBL20372960 | 0.74 | BRD4 (0.51) | ALDH1A1ESR1SMN1; SMN2KDM4E | |
| SCHEMBL21104554 | 0.74 | ALDH1A1 (0.47) | ALDH1A1ESR1SMN1; SMN2PKMMEN1 | |
| SCHEMBL19719158 | 0.74 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AKDM4EGRM2 | |
| SCHEMBL9001178 | 0.74 | HDAC8 (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885ESR1 4495/4885SMN1; SMN2 709/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885ESR1 4495/4885SMN1; SMN2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.